Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 200

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 200
---
 research performed
in such trial, and 2% of our net sales (minus the aforementioned marginal increase payment) received for the treatment of Squamous Cell
Carcinoma of the vulva, for three years from the date of first sale, world-wide.

On August 16, 2022, we entered
into a collaboration agreement with MIM Software, Inc. (“ MIM”) to provide treatment planning software for clinical sites using
the Alpha DaRT therapy. Under the terms of the agreement, the parties will collaborate on the use of MIM’s software suite, including
MIM Symphony®and MIMcloud®, for development of new features and support for the Alpha DaRT across multiple
potential indications, integration into all clinical trials involving the Alpha DaRT, and bundling the MIM software with the Alpha DaRT
for future commercial sales in territories where the Alpha DaRT and MIM’s software are both approved. The agreement contemplates
certain payments to MIM to be agreed between the parties upon initiating certain workstreams, as well as payments to MIM upon commercial
sale of the Alpha DaRT bundled with MIM’s software products.

Off-Balance Sheet Arrangements

We did not have during the
periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.

Quantitative and Qualitative Disclosures About
Market Risk

We are exposed to market risk
related to changes in interest rates. As of December 31, 2023 and 2024, our cash equivalents consisted of interest-bearing checking accounts
and deposits. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U. S.
interest rates. Due to the short-term nature and the low risk profile of our interest-bearing accounts, an immediate 10% change in interest
rates would not have a material effect on the fair market value of our cash and cash equivalents or on our financial position or results
of operations.

We operate primarily in Israel
and the majority of our expenses are denominated in NIS. We are subject to fluctuations in foreign currency rates in connection with these
arrangements. With respect to our foreign currency exposures for the years ended December 31, 2023 and 2024, a 10% unfavorable movement
in foreign currency exchange rates would have increased our operating expenses by approximately 4.5% and 4.7%, respectively.

We do not currently hedge